Pay in 4 interest-free payments of $5.55 Learn more
Ships within 48 hours · Estimated delivery Sep 5 - Sep 10
Continuous glucose monitoring (CGM) systems, increasingly available through the NHS for eligible patients, provide real-time glucose data and can alert users to falling glucose levels before symptoms develop
Remedies to Avoid or Treat Cautiously Activated Charcoal Activated charcoal is used in selected poisonings
Keratinocyte death by ferroptosis initiates skin inflammation after uvb exposure
Based on the typical UK regulatory pathway, the most realistic timeline is: Late 2026 / early 2027: Eli Lilly expected to submit regulatory filings to the FDA and MHRA following completion of the remaining TRIUMPH Phase 3 readouts Late 2027 to mid-2028: Possible MHRA marketing authorisation, allowing private UK prescribing 2028 to 2029 onwards: Possible NHS availability following a NICE technology appraisal and NHS commissioning decisions Timelines may differ across the four UK nations, as Scotland, Wales, and Northern Ireland assess medicines separately through the Scottish Medicines Consortium (SMC), All Wales Medicines Strategy Group (AWMSG), and the Department of Health Northern Ireland respectively
